PPL Therapeutics PLC
Best known for “Dolly the Sheep”, the world’s first mammal ‘cloned’ from an adult cell, the company developed the production of human pharmaceuticals using transgenic technology.
Full responsibility for the financial strategic planning, organisation and raising of equity and debt financing, financial management, HR, general administration and information technology.
Main Achievements: -
·Successful flotation on the London Stock Exchange raising £35m in 1996 and secondary (rights) issues raising a further £22m in 1998 and £32m in 2001
·Successfully raised £16m from three rounds of venture capital and two corporate investments
·Completed negotiation of major product collaboration and licensing package with Bayer Corporation (value over £60m)
·Negotiated funding proposals for the construction of the company's manufacturing plant from locations in Scotland, Germany, USA and New Zealand
·Completed detailed negotiations and agreed £42m funding package with Scottish Enterprise support
·Managed construction of a £10m GMP (Good Manufacturing Practice) pilot plant facility within budget
·Developed and implemented strategic and corporate plans
·Managed acquisition and integration of a US subsidiary and undertook due diligence on other M&A opportunities
·Created and administered foreign subsidiaries in USA and New Zealand
·Designed, implemented and maintained financial control systems which consistently controlled expenditure below budget
·Developed IT strategy and implemented Local Area Network and Virtual Private Network